Koa Shoji Holdings Co.,Ltd. (9273.T)
JPY 657.0
(-2.95%)
JPY 657.0
(-2.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.25 Billion JPY | 2.94% |
| 2022 | 2.19 Billion JPY | 3.11% |
| 2021 | 2.12 Billion JPY | -2.07% |
| 2020 | 2.17 Billion JPY | -7.27% |
| 2019 | 2.34 Billion JPY | -5.46% |
| 2018 | 2.47 Billion JPY | 11.9% |
| 2017 | 2.21 Billion JPY | -10.89% |
| 2016 | 2.48 Billion JPY | 24.11% |
| 2015 | 2 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 513.56 Million JPY | -4.79% |
| 2023 Q4 | 678.41 Million JPY | 32.1% |
| 2023 Q1 | 525.89 Million JPY | -21.34% |
| 2023 FY | 2.25 Billion JPY | 2.94% |
| 2023 Q2 | 539.41 Million JPY | 2.57% |
| 2022 Q4 | 668.6 Million JPY | 36.22% |
| 2022 FY | 2.19 Billion JPY | 3.11% |
| 2022 Q1 | 506.25 Million JPY | -21.69% |
| 2022 Q2 | 527.19 Million JPY | 4.14% |
| 2022 Q3 | 490.82 Million JPY | -6.9% |
| 2021 FY | 2.12 Billion JPY | -2.07% |
| 2021 Q4 | 646.5 Million JPY | 32.25% |
| 2021 Q3 | 488.83 Million JPY | -1.25% |
| 2021 Q2 | 495 Million JPY | -0.28% |
| 2021 Q1 | 496.38 Million JPY | -18.09% |
| 2020 Q2 | 499.13 Million JPY | -13.96% |
| 2020 Q1 | 580.09 Million JPY | -6.81% |
| 2020 FY | 2.17 Billion JPY | -7.27% |
| 2020 Q4 | 606 Million JPY | 24.56% |
| 2020 Q3 | 486.52 Million JPY | -2.53% |
| 2019 Q2 | 605.29 Million JPY | 2.67% |
| 2019 Q4 | 622.47 Million JPY | 18.62% |
| 2019 Q3 | 524.76 Million JPY | -13.3% |
| 2019 FY | 2.34 Billion JPY | -5.46% |
| 2019 Q1 | 589.53 Million JPY | -7.53% |
| 2018 Q3 | 614.33 Million JPY | 1.08% |
| 2018 Q1 | 617.71 Million JPY | 2.76% |
| 2018 FY | 2.47 Billion JPY | 11.9% |
| 2018 Q4 | 637.55 Million JPY | 3.78% |
| 2018 Q2 | 607.75 Million JPY | -1.61% |
| 2017 FY | 2.21 Billion JPY | -10.89% |
| 2017 Q4 | 601.13 Million JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2016 FY | 2.48 Billion JPY | 24.11% |
| 2015 FY | 2 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 94.827% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.914% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.584% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 98.858% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 39.586% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 96.561% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 92.223% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.577% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 57.265% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 96.57% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 95.121% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 80.461% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 72.579% |
| Tsumura & Co. | 48.8 Billion JPY | 95.374% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 93.226% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 88.446% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 96.458% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 82.166% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 94.422% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 95.027% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 45.699% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 62.03% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 56.779% |
| MedRx Co., Ltd | 959 Million JPY | -135.379% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | 21.451% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -52.933% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | 4.783% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 90.659% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 93.629% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -207.038% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 97.739% |